Mechanism of Action of Sacubitril/Valsartan in Heart Failure

Dual Component Mechanism

• Neprilysin is an endopeptidase that normally degrades several beneficial vasoactive peptides, including adrenomedullin, and other vasoactive peptides, as reported by the American Journal of Kidney Diseases 1, 2
• By inhibiting neprilysin, sacubitril increases the levels of these beneficial peptides, leading to vasodilation, as reported by the Journal of the American College of Cardiology 3
• The blockade of angiotensin II type-1 (AT1) receptor by valsartan prevents the harmful effects of angiotensin II, including sodium and water retention, as reported by the American Journal of Kidney Diseases 2
• Valsartan also inhibits angiotensin II-dependent aldosterone release, and sympathetic activation, as reported by the Journal of the American College of Cardiology 3

Pharmacodynamic Effects

• The administration of sacubitril/valsartan results in decreased plasma aldosterone and endothelin-1, as reported by the American Journal of Kidney Diseases 2
• The PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced the composite endpoint of cardiovascular death or heart failure hospitalization by 20% compared to enalapril, as reported by the Journal of the American College of Cardiology 3

Clinical Significance

• Sacubitril/valsartan is indicated for reducing the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF), as reported by the Journal of the American College of Cardiology 3 and Metabolism: Clinical and Experimental 4
• The American College of Cardiology recommends the use of sacubitril/valsartan in combination with other heart failure therapies in place of an ACE inhibitor or ARB, as reported by Circulation 5

Potential Side Effects and Interactions

• Common side effects of sacubitril/valsartan include hypotension, renal insufficiency, and hyperkalemia, as reported by the Journal of the American College of Cardiology 3
• Sacubitril/valsartan may lead to angioedema, though at a lower rate than ACE inhibitors, as reported by the Journal of the American College of Cardiology 3
• The American Heart Association reports that sacubitril inhibits OATP1B1, OATP1B3, OAT1, and OAT3 transporters, which may affect statin metabolism, as reported by Circulation 5, 6

Sacubitril Classification and Clinical Applications

Mechanism of Action and Pharmacological Classification

• The European Society of Cardiology (ESC) guidelines refer to sacubitril as a "neprilysin inhibitor" and the combination as an "angiotensin receptor neprilysin inhibitor" 7

Clinical Applications and Recommendations

• The ESC guidelines recommend sacubitril/valsartan for patients with chronic coronary syndromes and heart failure with reduced ejection fraction 7
• Sacubitril/valsartan has primary clinical use in heart failure management, although it was initially developed for hypertension 8

Pharmacodynamic Properties and Benefits

• The cardiovascular benefits of sacubitril/valsartan include vasodilation, reduced myocardial ischemia through decreased left ventricular wall stress, and improved coronary circulation 7

Hyperkalemia Risk with Entresto

Mechanism and Clinical Evidence

• The European Society of Cardiology recommends that Entresto (sacubitril/valsartan) is associated with hyperkalemia (elevated potassium), not hypokalemia (low potassium), and this risk is actually lower compared to traditional ACE inhibitors like enalapril 9
• Entresto decreases potassium excretion, making hyperkalemia the concern—not hypokalemia, as stated by the European Heart Society 9

Risk Factors and Monitoring

• Patients with chronic kidney disease, especially those with a creatinine clearance less than 30 mL/min, are at higher risk of hyperkalemia with Entresto, according to the European Heart Society 9, 10
• The American Heart Association suggests that concurrent use of mineralocorticoid receptor antagonists (such as spironolactone or eplerenone) increases the risk of hyperkalemia with Entresto 9
• Patients with diabetes mellitus are at higher risk of hyperkalemia with Entresto, as reported by the American Heart Association 11
• Regular monitoring of serum potassium and renal function is recommended before initiation and during treatment with Entresto, as advised by the European Heart Society 10

Practical Management

• The European Society of Cardiology recommends avoiding potassium supplements, salt substitutes, and high-potassium foods in patients taking Entresto to minimize the risk of hyperkalemia 11
• Patients taking Entresto should avoid NSAIDs, which further increase the risk of hyperkalemia, as stated by the European Heart Society 9
• Blood pressure should be monitored, as symptomatic hypotension is more common with Entresto than hyperkalemia, according to the European Heart Society 10

Mechanistic Rationale and Clinical Evidence for Sacubitril/Valsartan in Heart Failure

Mechanism of Action

• Dual pharmacologic target – Sacubitril inhibits the neprilysin enzyme while valsartan blocks the angiotensin‑II type‑1 (AT1) receptor; together they augment vasodilation and suppress maladaptive neuro‑hormonal activation in patients with heart failure. 12
• Neprilysin profile – Neprilysin is a zinc‑dependent metalloprotease that normally degrades several protective vasoactive peptides (e.g., atrial, B‑type, and C‑type natriuretic peptides; adrenomedullin; bradykinin; substance P), which play key roles in mitigating heart‑failure pathophysiology. 12
• Necessity of ARB co‑administration – Because neprilysin also degrades angiotensin II, isolated neprilysin inhibition would raise angiotensin II levels and potentially worsen heart failure; concomitant AT1‑receptor blockade with valsartan prevents this paradoxical effect. 12

Pharmacologic Rationale for Using an ARB Instead of an ACE Inhibitor

• Avoidance of bradykinin‑mediated angioedema – ACE inhibitors and neprilysin inhibitors both increase bradykinin concentrations; their combination markedly raises the risk of life‑threatening angioedema, making the combination contraindicated. 12
• ARBs do not affect bradykinin metabolism – Valsartan, an ARB, provides AT1‑receptor blockade without influencing bradykinin degradation, allowing safe co‑administration with sacubitril. 12

Clinical Efficacy (PARADIGM‑HF Trial)

• Outcome benefit – In the large, randomized PARADIGM‑HF trial, sacubitril/valsartan reduced the composite endpoint of cardiovascular death or heart‑failure hospitalization by 20 % compared with enalapril, establishing superiority over standard ACE‑inhibitor therapy. Evidence level: Class I, Level A (large RCT). 12

Safety Considerations

• Contraindication with ACE inhibitors – Co‑administration of sacubitril/valsartan and any ACE inhibitor is prohibited because of the synergistic rise in bradykinin and the consequent high risk of angioedema. 12

Drug Interaction Effects of Entresto (Sacubitril/Valsartan)

Transporter Inhibition

• Sacubitril inhibits the hepatic and renal drug transporters OATP1B1, OATP1B3, OAT1, and OAT3, potentially altering the pharmacokinetics of co‑administered agents such as statins. 13

Statin Pharmacokinetic Interaction

• When Entresto is given together with atorvastatin, the atorvastatin peak plasma concentration (Cmax) increases up to two‑fold and its area under the curve (AUC) rises by roughly 30%; clinical trials did not observe significant adverse events, but a lower statin dose may be prudent. 13